Stoke Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview

Stoke Therapeutics

04/11/2022 17:22

* Stoke Therapeutics Inc  STOK.OQ   STOK.O  is expected
to show a
rise in quarterly revenue when it reports  results on November 7
(estimated). 
    * The Bedford Massachusetts-based  company is expected to
report
revenue of $2.45 million, according to the mean estimate from 10
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Stoke Therapeutics
Inc is
for a loss of 68 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $50​, above​ its last closing price
of $11.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.69       -0.69      -0.63     Beat    8.4
 Mar. 31 2022  0.37        0.36       -0.66     Missed  -282.2
 Dec. 31 2021  -0.64       -0.62      -0.66     Missed  -5.9​
 Sep. 30 2021  -0.61       -0.59      -0.61     Missed  -3.8
 ​​Jun.        -0.45       -0.47      -0.60     Missed  -27.7
 30 2021                                                
 Mar. 31 2021  -0.44       -0.44      -0.46     Missed  -4.5​
 Dec. 31 2020  -0.41       -0.42      -0.42     Met     -0.2
 Sep. 30 2020  -0.44       -0.41      -0.41     Met     1
 This summary was machine generated November 4 at 17:21 GMT.  All
figures in US dollars  unless otherwise stated